A new cell therapy sector arising from the convergence of cell and gene therapy

Cytotherapy ◽  
2013 ◽  
Vol 15 (4) ◽  
pp. S52 ◽  
Author(s):  
E.J. Culme-Seymour ◽  
S. Edwards-Parton ◽  
J. Carmen ◽  
W. Folkerts ◽  
D. Smith ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Cell Therapy ◽  
Cell And Gene Therapy

scholarly journals Understanding and Prevention of “Therapy-” Induced Dyskinesias

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Iciar Aviles-Olmos ◽  
Zinovia Kefalopoulou ◽  
Thomas Foltynie
Keyword(s):  
Gene Therapy ◽  
Synaptic Plasticity ◽  
Basal Ganglia ◽  
Cell Therapy ◽  
Dopamine Release ◽  
The Subject ◽  
Cell And Gene Therapy ◽  
Further Development ◽  
Gene And Cell Therapy

L-dopa is the most effective, currently available treatment for Parkinson’s disease (PD), but it leads to the development of involuntary movements known as L-dopa-induced dyskinesia (LID) in the majority of patients after long-term use. Both gene and cell therapy approaches are the subject of multiple ongoing studies as potential ways of relieving symptoms of PD without the complication of dyskinesia. However, the spectre of dyskinesia in the absence of L-dopa, the so-called “off-phase” or graft-induced dyskinesia (GID), remains a major obstacle particularly in the further development of cell therapy in PD, but it is also a concern for proponents of gene therapy approaches. LID results from nonphysiological dopamine release, supersensitivity of dopamine receptors, and consequent abnormal signalling through mechanisms of synaptic plasticity. Restoration of physiological circuitry within the basal ganglia loops is ultimately the aim of all cell and gene therapy approaches but each using distinctive strategies and accompanied by risks of exacerbation of LID or development of “off-phase”/GID. In this paper we discuss the details of what is understood regarding the development of dyskinesias with relevance to cell and gene therapy and potential strategies to minimize their occurrence.

scholarly journals Accelerating Innovation in the Creation of Biovalue

2017 ◽  
Vol 42 (5) ◽  
pp. 925-946 ◽  
Author(s):  
John Gardner ◽  
Andrew Webster
Keyword(s):  
Gene Therapy ◽  
Regenerative Medicine ◽  
Cell Therapy ◽  
Sociotechnical Imaginaries ◽  
The Creation ◽  
Cell And Gene Therapy

The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to “accelerate” innovation. This article examines in detail one such agency, the United Kingdom’s Cell and Gene Therapy Catapult (CGTC). We describe CGTC’s role as an accelerator agency and its value narrative, which combines both “health and wealth.” Drawing on the notion of sociotechnical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.

Attenuating Muscle Wasting: Cell and Gene Therapy Approaches

2003 ◽  
Vol 4 (7) ◽  
pp. 575-585 ◽  
Author(s):  
A. Musaro ◽  
N. Rosenthal
Keyword(s):  
Gene Therapy ◽  
Muscle Wasting ◽  
Cell And Gene Therapy

Fetal stem cell and gene therapy

2017 ◽  
Vol 22 (6) ◽  
pp. 410-414 ◽  
Author(s):  
Russell Witt ◽  
Tippi C. MacKenzie ◽  
William H. Peranteau
Keyword(s):  
Gene Therapy ◽  
Stem Cell ◽  
Fetal Stem Cell ◽  
Cell And Gene Therapy

How institutional biosafety committees contribute to safety, capacity and regulatory approvals in cell and gene therapy trials

Cytotherapy ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. S206
Author(s):  
G. O’Sullivan ◽  
B. Yu ◽  
C. Bailey ◽  
Z. Velickovic ◽  
J. Rasko
Keyword(s):  
Gene Therapy ◽  
Cell And Gene Therapy
Sign in / Sign up

Export Citation Format

Share Document